Search the Newsreel

Biocon Limited Actuals & Estimates (NSE:BIOCON)

Barinthus (BRNS) Earnings Check: EPS Exceeds Its Estimate in the Current Update; The Market Price Advances 4.47% at the Close - EBITDA Margin Trends

Barinthus (BRNS) Earnings Check: EPS Exceeds Its Estimate in the Current Update; The Market Price Advances 4.47% at the Close - Profit Inflection Point

Bio-Techne (TECH) CEO exercises awards, 10.8K shares withheld

Bio-Techne CEO Kim Kelderman reported multiple equity award updates on August 15, 2026, acquiring 21,470 shares of common stock through exercises while 10,821 shares were withheld for tax and exercise costs. The Board authorized discretionary vesting for certain performance restricted stock units and options, …

Bio-Techne (TECH) CFO exercises awards, covers taxes in stock

Bio-Techne (TECH) CFO James Hippel reported equity-award transactions on August 15, 2026, acquiring 9,779 common shares through restricted stock unit exercises and having 4,310 shares withheld at $72.40 for tax liabilities. The board also authorized discretionary vesting for 866 performance RSUs and 2,332 performance …

Bio-Techne (NASDAQ: TECH) exec updates option and RSU holdings

William Geist, President of Protein Sciences at Bio-Techne Corp (TECH), has reported 13 insider transactions involving grants of restricted stock units. The Form 4 filing details direct holdings including 44,596 Restricted Stock Units, 123,059 Stock Options (Right to Buy), 35,093 Performance Restricted Stock Units, …

ETFs Investing in Fortress Biotech, Inc. Stocks

This article lists ETFs that include Fortress Biotech, Inc. (FBIO) stocks, highlighting how these funds make investing in stocks more accessible and potentially lower risk. It provides a table with details on two such ETFs: iShares Microcap ETF (IWC) and EA Bridgeway Omni Small-Cap …

Pacira BioSciences (PCRX) CMO sells 3,040 shares in 10b5-1 plan

Pacira BioSciences (PCRX) Chief Medical Officer, Jonathan Slonin, sold 3,040 shares of common stock on August 17, 2026, at $23.23 per share through an open-market transaction. This sale was conducted under a Rule 10b5-1 trading plan adopted on August 12, 2025. Following the transaction, …

Biogen Inc. stock underperforms Tuesday when compared to competitors despite daily gains

Shares of Biogen Inc. (BIIB) rose 1.63% on Tuesday to $212.55, breaking a two-day losing streak, despite a generally grim trading session for the broader stock market. The S&P 500 Index fell 0.69% and the Dow Jones Industrial Average declined 0.22%. Despite its daily …

BioMarin looks to spur growth with potential $490M buyout of Dutch bone drug company

BioMarin Pharmaceutical is reportedly looking to acquire Dutch bone drug company Alesa Therapeutics for up to $490 million, including a $275 million upfront payment. This potential acquisition comes shortly after BioMarin decided to halt the late-stage development of another drug. The move is seen …

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

Sabrina Martucci Johnson, CEO of Daré Bioscience, has been recognized on Forbes' 2026 “50 Over 50: Innovation” list for her significant impact in women's health. The company, founded in 2015, is evolving from a clinical-stage biotechnology firm to a multi-product women's health company with …

The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability

Vir Biotechnology (VIR) reported a significant swing to profitability in Q2 2026, with revenues reaching US$238.95 million and net income of US$80.08 million, replacing a prior net loss. This unexpected financial performance, driven partly by a collaboration with Astellas, alters the investment narrative by …

Legend Biotech (LEGN) RSU grant lifts interim CEO stake to 35,142 shares

Legend Biotech (LEGN) Interim CEO Alan Bash received a grant of 4,908 restricted share units (RSUs) on August 14, 2026, increasing his direct holdings to 35,142 ordinary shares. These RSUs will vest in three equal annual installments starting July 27, 2027, provided he remains …

Bio-Techne (TECH) awards give executive 5,423 shares, 1,947 withheld

Bio-Techne (TECH) executive Steven C. Crouse, President - Diag & Spatial Bi, converted 5,423 restricted stock units into common stock on August 15, 2026. In connection with this, 1,947 shares were withheld at $72.40 per share to cover exercise price or tax liabilities. Crouse …

Bio-Techne (TECH) director exercises 589 RSUs, uses shares for taxes

Bio-Techne (TECH) director Amy E. Herr reported the exercise of 589 restricted stock units (RSUs) indirectly through her significant other on August 15, 2026. A portion of these shares, 213 common shares, were subsequently used to cover tax liabilities at a price of $72.40 …

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma announced inducement grants totaling 11,000 restricted stock units (RSUs) to newly hired employees. These grants, made on August 17, 2026, are a material inducement for employment, aligning with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal installments over a …

New Zenas BioPharma hires receive stock awards vesting through 2030

Zenas BioPharma announced on August 18, 2026, that its Board Compensation Committee granted 11,000 restricted stock units (RSUs) to newly hired employees as inducement awards. These RSUs, issued under Nasdaq Listing Rule 5635(c)(4) and the company’s 2026 Inducement Plan, will vest in four equal …

Lakefront Biotherapeutics (LKFT) spends €2.6M on August share buyback

Lakefront Biotherapeutics (LKFT) reported repurchasing 107,871 ordinary shares between August 10 and 14, 2026, as part of its ongoing share repurchase program. The company spent an aggregate of €2,604,002.56 at an average price of €24.14 per share, with prices ranging from €22.88 to €24.98. …

First Tracks (TRAX) insider records new share trades

Benjamin Stone, Chief Business Officer at First Tracks Biotherapeutics, Inc. (TRAX), reported a transaction involving 60,492 performance stock units (PSUs) on August 15, 2026. These PSUs were earned upon the achievement of performance criteria and represent a conditional right to receive shares of common …

Legend Biotech (NASDAQ: LEGN) targets 19.1M new stock awards

Legend Biotech Corporation (LEGN) will hold its Annual General Meeting on September 24, 2026, to vote on several key proposals, including a significant increase in its equity reserve. The company is seeking shareholder approval to boost its 2020 Restricted Shares Plan by 19.1 million …

Solid Biosciences LLC (NASDAQ: SLDB) Share Price, SLDB Stock News, SLDB Share Price & Updates

BioHarvest (BHST) Earnings Recap: The Available Earnings Metric Delivers a Miss in the Reported Period; The Stock Loses 1.15% in the Available Record - Earnings Manipulation Risk

Generate (GENB) Report Card: EPS Misses Its Estimate in the Available Record; Price Action: Shares Finish 3.44% Higher in the Current Update - EPS Guidance Update

Castle Biosciences (CSTL) CFO sells 24,908 company shares

Castle Biosciences (CSTL) Chief Financial Officer, Frank Stokes, sold 24,908 shares of common stock on August 14, 2026, at a weighted-average price of $29.77 per share. The transaction, executed in multiple trades between $29.71 and $29.97, resulted in Stokes directly holding 35,177 shares after …

BioLineRx (NASDAQ: BLRX) flags dilution risk in new share plan

BioLineRx Ltd. (BLRX) is seeking shareholder approval to significantly increase its authorized share capital from 20 billion to 100 billion ordinary shares at its Annual General Meeting on September 23, 2026. The company warns that this substantial increase could lead to dilution of voting …

Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $30

Stifel has reiterated its Buy rating on Crescent Biopharma (CBIO.US) and maintained its target price at $30. This suggests a continued positive outlook from the firm regarding the company's stock performance.

S&P downgrades Emergent BioSolutions outlook on competition

S&P Global Ratings has downgraded Emergent BioSolutions Inc.'s outlook to negative from stable due to increased competition in the naloxone market, which led to reduced revenue guidance. The ratings agency projects a significant decline in both its commercial and Medical Countermeasures segments' revenue for …

bioAffinity's lung cancer test will be marketed to VA medical centers nationwide

bioAffinity Technologies has signed a distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business (SDVOSB), to market its noninvasive lung cancer diagnostic, CyPath Lung, to federal healthcare agencies, including VA medical centers nationwide. This partnership significantly expands bioAffinity's commercial reach and provides veterans with …

bioAffinity Technologies expands CyPath Lung federal distribution

bioAffinity Technologies (BIAF) has partnered with AvMEDICAL for nationwide distribution of its CyPath Lung test to federal healthcare agencies, including VA medical centers. This collaboration aims to expand CyPath Lung's presence in the federal supply chain, improving early lung cancer detection for veterans and …

NovaBridge (NBP) Latest Results Brief: Profit Per Share Falls Below Its Benchmark in Latest Trading; Post-Earnings Trading: The Stock Ends Down 2.07% in the Current Update - Operating Income Trends

Cogent (COGT) Q1 2026 Earnings: EPS Misses Its Estimate in the Latest Session; Investor Response: The Share Price Sheds 1.35% in Latest Trading - CEO Earnings Statement

Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy - Slideshow (NASDAQ:CLRB) 2026-08-18

Cellectar Biosciences, Inc. (CLRB) discussed the scientific rationale and potential of its Phospholipid Ether Platform in targeted cancer therapy. This information was presented in a slideshow in conjunction with an event. The article highlights the company's focus on developing cancer therapies using this platform.

Why Helix BioPharma Corp. stock is gaining today

Pulse (PLSE) Earnings Review: EPS Exceeds Its Estimate in the Current Update; Reaction Snapshot

Innovent Biologics (SEHK:1801), Why Is It Back In The Spotlight?

Revenue per share of Gossamer Bio, Inc. – HAM:4GB

This article provides financial information for Gossamer Bio, Inc. (HAM:4GB), specifically focusing on its revenue per share. The data is sourced from ICE Data Services and FactSet, with SEC filings provided by Quartr. The company's stock is traded on the Hamburg Stock Exchange.